-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41

Benzinga·11/16/2026 14:07:10
Listen to the news
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.